1. For the remainder of the chapter we confine the discussion to the IND process for drugs regulated through the FDA’s Center for Drug Evaluation and Research (CDER). A similar process is required in the Investigational Device Exemption (IDE) filing for a device regulated through the FDA’s Center for Devices and Radiological Health (CDRH).
2. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjugate Chemistry 2003; 14: 388–394.
3. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives 2005; 113: 823–839.
4. Furumoto K, Nagayama S, Ogawara K, Takakura Y, Hashida M, Higaki K, Kimura T. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. Journal of Controlled Release 2004; 97: 133–141.
5. Oberdorster G. Toxicology of ultrafine particles: in vivo studies. Philosophical Transactions of the Royal Society of London Series A, Mathematical Physical and Engineering Sciences 2000; 358: 2719–2739.